February 2018
| HTA ID | Drug | Brand | Indication | Assessment status | Date | |
| - | Benralizumab | Fasenra® | As add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β-agonists. | Rapid Review complete | 14th February 2018 |  |
| - | Dimethyl fumarate | Skilarence® | For the treatment of moderate to severe plaque psoriasis in adults in need of systemic medicinal therapy. | Rapid Review Complete | 6th February 2018 | |
| - | Guselkumab | Tremfya® | For the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. | Assessment process complete | 6th February 2018 | |
